Thematic evaluation
Back to company overview

Stryker Corp. (SYK)

September 06, 2024

Compared to: Boston Scientific Corp. (BSX) | Medtronic Plc (MDT) | Health Care Select Sector SPDR Fund (XLV)

Our reasoning

Stryker's current valuation appears fair, balancing its strong financial performance and growth prospects against potential risks. The company's valuation multiples are in line with peers and historical averages, suggesting the market has appropriately priced in both the company's strengths and challenges. While there is potential for upside in an optimistic scenario, the base case aligns closely with current valuation levels.

Key takeaways
  • Stryker is a leading global medical technology company with a strong financial performance, a diverse product portfolio, and a robust growth strategy.
  • The company's key strengths include its strong brand, innovative products, global reach, and efficient operations.
  • Stryker's recent acquisitions of Cerus and SERF indicate its strategic focus on strengthening its market position and product offerings, particularly in the high-growth Neurovascular and Joint Replacement segments.
  • The company's international expansion strategy, particularly in emerging markets, presents significant growth opportunities.
  • Stryker's valuation is generally in line with its peers, suggesting that it is fairly valued.
  • The company's future outlook is positive, with management expecting continued growth and margin expansion.
  • However, investors should be aware of the company's risks and threats, including reliance on global supply chains, intense competition, and regulatory compliance issues.
  • Overall, Stryker is a well-managed company with a strong track record of financial performance and a promising future.
Fairly valued
Ask a question about Stryker Corp. (SYK)
Evaluation summary

  1. Company Overview:

    • Stryker is a global leader in medical technology, offering a diverse portfolio of products and services across three segments: MedSurg and Neurotechnology, Orthopaedics, and Spine.
    • The company's product offerings include surgical equipment, patient handling and safety technologies, endoscopic and communications systems, neurosurgical and neurovascular devices, joint replacement and trauma implants, and spinal devices.
    • Stryker serves a global customer base of healthcare providers, with sales in approximately 75 countries through company-owned subsidiaries and third-party distributors.
    • The company's primary competitors include Zimmer Biomet, Medtronic, Johnson & Johnson, Smith & Nephew, and other medical technology companies.
    • For comparative analysis, we will be using the Health Care Select Sector SPDR Fund (XLV) as a benchmark and Medtronic Plc (MDT) and Boston Scientific Corp. (BSX) as industry peers.

  2. Financial Performance:

    • Stryker has consistently demonstrated strong financial performance, with double-digit revenue growth and expanding profit margins over the past several years.
    • Revenue growth has been driven by strong demand for its products and services across multiple segments, particularly in endoscopy, medical divisions, and Mako installations.
    • The company's international expansion, with high single-digit to double-digit growth in key markets, is a significant growth catalyst.
    • The shift towards ambulatory surgical centers (ASCs) continues to be a favorable trend for Stryker, as the company is well-positioned to capitalize on this market dynamic.
    • Stryker's profitability is strong, with expanding gross, operating, and net margins.
    • The company's focus on margin expansion through pricing initiatives, manufacturing efficiencies, and SG&A leverage is paying off.
    • The company's profitability ratios are significantly higher than the industry average, indicating a strong competitive position and efficient operations.
    • Stryker's ROA, ROE, and ROIC ratios are consistently higher than its peers, indicating superior asset utilization and profitability.

  3. Operational Efficiency:

    • Stryker maintains a strong liquidity position, with ample cash and short-term investments.
    • The company's increasing current assets and decreasing short-term debt suggest a focus on managing working capital and maintaining financial flexibility.
    • The company's long-term solvency appears strong, with a decreasing long-term debt and a healthy debt-to-equity ratio.
    • The company's conservative approach to financing and commitment to financial stability are reflected in its low debt levels and strong debt coverage ratios.
    • Stryker demonstrates effective expense control, with operating expenses increasing at a slower rate than revenue.
    • The company's asset utilization efficiency is high, as evidenced by the strong return on assets and return on equity ratios.
    • Stryker's cash flow generation is strong, driven by its core business operations and investments in growth initiatives.
    • The company's free cash flow generation is expected to continue to support debt repayment, dividend growth, and investments in organic growth opportunities.
    • The company's cash flow ratios are significantly higher than the industry average, indicating a strong ability to generate cash flow from operations.
    • Stryker's capital expenditure analysis reveals a consistent investment in its core business, with depreciation trends aligning with the company's growth strategy.
    • The company's dividend and share repurchase program is sustainable, supported by its strong cash flow generation and commitment to shareholder value creation.
    • Stryker's liquidity ratios are consistently higher than its peers, indicating a stronger ability to meet short-term obligations.
    • The company's debt-to-equity and leverage ratios are lower than its peers, indicating a more conservative approach to financing and a lower risk profile.

  4. Growth Opportunities:

    • Stryker is well-positioned for continued growth, driven by its diverse business model, innovative product portfolio, and robust demand for capital products.
    • The company's international expansion strategy, particularly in emerging markets, presents significant growth opportunities.
    • The shift towards ASCs is a favorable trend for Stryker, as the company is well-positioned to capitalize on this market dynamic.
    • Stryker's recent acquisitions of Cerus and SERF indicate its strategic focus on strengthening its market position and product offerings, particularly in the high-growth Neurovascular and Joint Replacement segments.
    • The company's R&D pipeline is robust, with several promising new products and technologies in development, including Mako Spine and Mako Shoulder.
    • Stryker's capital allocation strategy is focused on acquisitions, dividends, and share repurchases, which are aligned with the company's growth strategy and shareholder value creation.
    • Management's historical execution of strategic plans has been successful, with the company consistently exceeding its financial targets.

  5. Risks and Threats:

    • Stryker faces several risks and threats, including reliance on global supply chains, intense competition, maintaining relationships with healthcare professionals, cybersecurity threats, and legal/regulatory compliance issues.
    • The company's reliance on global supply chains exposes it to potential shortages, price increases, and availability issues.
    • Intense competition in product development and innovation is a significant challenge for Stryker.
    • Maintaining relationships with healthcare professionals is crucial for the company's success, as it relies on their adoption of its products and services.
    • Cybersecurity risks and potential IT system failures or breaches could disrupt the company's operations and damage its reputation.
    • Regulatory compliance risks, including with the European Union Medical Device Regulation, could increase the company's costs and complexity.
    • Legal and product liability risks, including ongoing investigations and recalls, could damage the company's reputation and financial performance.

  6. Valuation Analysis:

    • Stryker's valuation metrics, including P/E, EV/EBITDA, and price-to-sales, are generally in line with its peers, suggesting that the company is fairly valued.
    • The company's strong financial performance, growth prospects, and robust cash flow generation support its current valuation.
    • Potential catalysts for future growth include the continued expansion of the Mako robotic platform, the launch of new products and technologies, and the company's international expansion strategy.

  7. Price Performance:

    • Stryker's stock price has generally outperformed the Health Care Select Sector SPDR Fund (XLV) over the past three years, with the exception of the past six months.
    • The company's stock price has been more volatile than XLV's, indicating that SYK is a riskier investment.
    • Stryker's stock price has generally outperformed MDT over the past three years, particularly in the longer timeframes (2 years and 3 years).
    • However, SYK has consistently underperformed BSX, especially in the shorter timeframes (1 week, 1 month, 3 months, and 6 months).
    • This suggests that SYK may be a more suitable investment for long-term investors who are willing to accept some short-term volatility.

  8. Future Outlook:

    • Stryker's management has expressed confidence in the company's ability to sustain high organic growth, citing the strength of the product pipeline, innovation cycle, and international expansion opportunities.
    • The company's guidance for 100 basis points of operating margin expansion in 2024 and 2025 suggests a continued focus on profitability and efficiency.
    • Analyst estimates for Stryker's future performance are generally positive, with consensus expectations for continued revenue growth and margin expansion.

  9. Summary:

    • Stryker is a leading global medical technology company with a strong financial performance, a diverse product portfolio, and a robust growth strategy.
    • The company's key strengths include its strong brand, innovative products, global reach, and efficient operations.
    • However, Stryker faces several risks and threats, including reliance on global supply chains, intense competition, and regulatory compliance issues.
    • The company's valuation is generally in line with its peers, suggesting that it is fairly valued.
    • Stryker's stock price has generally outperformed its benchmark and MDT, but it has underperformed BSX.
    • The company's future outlook is positive, with management expecting continued growth and margin expansion.
    • Overall, Stryker is a well-managed company with a strong track record of financial performance and a promising future.
    • However, investors should be aware of the company's risks and threats before making any investment decisions.
Peer fundamentals 
Fundamentals
Insights
  • Stryker is a leading global medical technology company with a diverse portfolio of innovative products and services across multiple high-growth segments, including MedSurg, Neurotechnology, Orthopaedics and Spine.
  • The company has demonstrated strong financial performance, with double-digit revenue growth, expanding profit margins, and a solid liquidity position, despite facing industry-wide challenges like pricing pressures, supply chain disruptions, and regulatory compliance requirements.
  • Stryker's recent acquisitions of Cerus and SERF indicate its strategic focus on strengthening its market position and product offerings, particularly in the high-growth Neurovascular and Joint Replacement segments.
  • Key risks include reliance on global supply chains, intense competition, maintaining relationships with healthcare professionals, cybersecurity threats, and legal/regulatory compliance issues, including ongoing investigations and product liability claims.
  • Management's disciplined approach to capital allocation, with a focus on acquisitions, dividends, and share repurchases, appears to be supporting the company's growth strategy and shareholder value creation.
  • The company's cash flow generation is strong, driven by its core business operations and investments in growth initiatives.
  • The company's free cash flow generation is expected to continue to support debt repayment, dividend growth, and investments in organic growth opportunities.
  • The company's cash flow ratios are significantly higher than the industry average, indicating a strong ability to generate cash flow from operations.
  • Stryker is well-positioned for continued growth, driven by its diverse business model, innovative product portfolio, and robust demand for capital products.
  • The company's strong financial performance, expanding profit margins, and solid liquidity position suggest a bright future.
  • The company's strategic initiatives, including recent acquisitions and upcoming product launches, position it well to maintain its growth momentum and competitive edge in the market.
Analysis
  • Revenue - Stryker's revenue growth is driven by strong demand for its products and services across multiple segments, particularly in endoscopy, medical divisions, and Mako installations. - The company's international expansion, with high single-digit to double-digit growth in key markets, is a significant growth catalyst. - The shift towards ambulatory surgical centers (ASCs) continues to be a favorable trend for Stryker, as the company is well-positioned to capitalize on this market dynamic.
    • Profitability
      • Stryker's profitability is strong, with expanding gross, operating, and net margins.
      • The company's focus on margin expansion through pricing initiatives, manufacturing efficiencies, and SG&A leverage is paying off.
      • The company's profitability ratios are significantly higher than the industry average, indicating a strong competitive position and efficient operations.
    • Liquidity
      • Stryker maintains a strong liquidity position, with ample cash and short-term investments.
      • The company's increasing current assets and decreasing short-term debt suggest a focus on managing working capital and maintaining financial flexibility.
    • Solvency
      • The company's long-term solvency appears strong, with a decreasing long-term debt and a healthy debt-to-equity ratio.
      • The company's conservative approach to financing and commitment to financial stability are reflected in its low debt levels and strong debt coverage ratios.
    • Operational Efficiency
      • Stryker demonstrates effective expense control, with operating expenses increasing at a slower rate than revenue.
      • The company's asset utilization efficiency is high, as evidenced by the strong return on assets and return on equity ratios.
    • Cash Flow Analysis
      • The company's cash flow generation is strong, driven by its core business operations and investments in growth initiatives.
      • The company's free cash flow generation is expected to continue to support debt repayment, dividend growth, and investments in organic growth opportunities.
      • The company's cash flow ratios are significantly higher than the industry average, indicating a strong ability to generate cash flow from operations.
    • Risk Factors
      • Reliance on global supply chains and third-party suppliers, exposing the company to potential shortages, price increases, and availability issues.
      • Pricing pressures from cost containment measures, healthcare system consolidation, and government procurement programs.
      • Intense competition in product development and innovation.
      • Challenges in maintaining relationships with healthcare professionals.
      • Cybersecurity risks and potential IT system failures or breaches.
      • Regulatory compliance risks, including with the European Union Medical Device Regulation.
      • Legal and product liability risks, including ongoing investigations and recalls.
    • Future Outlook
      • Stryker is well-positioned for continued growth, driven by its diverse business model, innovative product portfolio, and robust demand for capital products.
      • The company's strong financial performance, expanding profit margins, and solid liquidity position suggest a bright future.
      • The company's strategic initiatives, including recent acquisitions and upcoming product launches, position it well to maintain its growth momentum and competitive edge in the market.
Most recent earnings report
Financial statements 
All public filings
Comparative Analysis
Benchmarks (as of 2024-08-20)
Health Care Select Sector SPDR Fund (XLV)
  • Performance Comparison:
    • SYK has generally outperformed XLV over the past three years, with the exception of the past six months. This suggests that SYK has been a strong performer, but its recent performance has been weaker.
    • SYK's performance has been more volatile than XLV's, indicating that SYK is a riskier investment.
  • Risk and Return Analysis:
    • SYK has provided higher annualized returns than XLV over the past three years. However, its volatility has also been higher, indicating that the higher returns come with a higher risk.
    • SYK's annualized volatility has been consistently higher than XLV's, indicating that SYK is a riskier investment.
    • SYK has experienced larger maximum drawdowns than XLV, indicating that SYK is more susceptible to market downturns.
  • Risk-Adjusted Performance:
    • XLV has consistently offered a better risk-adjusted return than SYK, as indicated by its higher Sharpe ratio.
    • SYK's beta suggests that it is more sensitive to market movements than XLV. This indicates that SYK is a riskier investment than XLV.
  • Overall Assessment:
    • SYK has been a strong performer over the past three years, but its recent performance has been weaker. Its higher volatility and larger drawdowns suggest that it is a riskier investment than XLV.
    • While SYK has provided higher returns, XLV has offered a better risk-adjusted return.
    • Investors who are comfortable with higher risk may consider SYK, but those who prefer a more stable investment may prefer XLV.
    • It is important to note that past performance is not indicative of future results. Investors should carefully consider their own risk tolerance and investment goals before making any investment decisions.
Peers Price History(as of 2024-09-04)
Boston Scientific Corp. (BSX)Medtronic Plc (MDT)
  • Performance Comparison:
    • SYK has generally outperformed MDT over the past three years, particularly in the longer timeframes (2 years and 3 years). However, SYK has consistently underperformed BSX, especially in the shorter timeframes (1 week, 1 month, 3 months, and 6 months). This suggests that SYK may be a more suitable investment for long-term investors who are willing to accept some short-term volatility.
  • Risk and Return Analysis:
    • SYK has provided higher annualized returns than MDT over the past three years. However, SYK's annualized returns have been lower than those of BSX. This suggests that SYK may be a more balanced investment than MDT, but it may not offer the same growth potential as BSX.
    • SYK's annualized volatility has been higher than that of MDT but lower than that of BSX. This suggests that SYK may be a more volatile investment than MDT, but it may be less volatile than BSX.
    • SYK's maximum drawdown of 31.68% is lower than MDT's 45.1% but higher than BSX's 25.18%. This indicates that SYK may be more resilient to market downturns than MDT, but it may be less resilient than BSX.
  • Risk-Adjusted Performance:
    • SYK has generally had a higher Sharpe Ratio than MDT and BSX, indicating that it has offered better risk-adjusted returns. This suggests that SYK may be a more efficient investment than its peers, as it has been able to generate higher returns for a given level of risk.
    • SYK's beta of above 1 suggests that it is more sensitive to market movements than MDT and BSX. This means that SYK's stock price is likely to fluctuate more than those of its peers during periods of market volatility.
  • Overall Assessment:
    • SYK has generally outperformed MDT in terms of both absolute and risk-adjusted returns. However, SYK has underperformed BSX in terms of both absolute returns and risk-adjusted returns. SYK's higher beta suggests that it has a higher risk profile than MDT and BSX. This means that SYK's stock price is likely to fluctuate more than those of its peers during periods of market volatility. However, SYK's lower maximum drawdown and shorter drawdown durations suggest that it may be more resilient to market downturns than MDT and BSX. Overall, SYK appears to be a more balanced investment than MDT, but it may not offer the same growth potential as BSX. Investors should carefully consider their risk tolerance and investment goals before making any investment decisions.
Peers Fundamentals(as of 2024-06-30)
Boston Scientific Corp. (BSX)Medtronic Plc (MDT)

  1. Market Position and Size:

    • SYK is the largest company in the peer group, with a market capitalization significantly larger than its peers, Medtronic Plc (MDT) and Boston Scientific Corp. (BSX).
    • While SYK's revenue, EBITDA, and net income are also larger than its peers, they are not proportionally so, suggesting a potential premium valuation.

  2. Profitability and Efficiency:

    • SYK exhibits strong profitability metrics, exceeding both peer and industry averages in Gross Profit Margin, EBITDA Margin, and Net Profit Margin.
    • SYK demonstrates high efficiency in generating returns, with superior Return on Average Assets, Return on Average Total Equity, Return on Average Total Capital, and Return On Average Invested Capital compared to peers and industry averages.

  3. Financial Health and Stability:

    • SYK's liquidity ratios are slightly lower than peer averages, but its manageable debt levels and strong cash flow generation provide a buffer against potential financial risks.
    • Its balance sheet structure is generally in line with peer averages, considering relative company sizes, suggesting a more efficient use of capital.

  4. Valuation and Market Perception:

    • SYK's valuation metrics, particularly its EV/Sales and P/E ratios, suggest a premium valuation compared to its peers and industry standards.
    • This premium valuation could be attributed to its strong profitability, efficiency, and growth prospects.

  5. Cash Flow and Capital Management:

    • SYK's cash flow metrics are generally strong, with a free cash flow that is comparable to its peers, despite a lower net operating cash flow.
    • Its significantly lower capital expenditures compared to peers contribute to its strong free cash flow generation.

  6. Growth and Future Prospect:

    • SYK exhibits strong growth trends in several key metrics, consistently outperforming the peer group average in sales revenue, EBITDA, net income, and basic earnings per share.
    • Its 3-year CAGR is generally higher than its 5-year CAGR for most metrics, indicating a potential acceleration in growth.
    • SYK's strong growth trends suggest a strong market share and a competitive advantage in the medical technology industry.

  7. Potential for Investment:

    • SYK presents an attractive investment opportunity, considering its strong financial performance, growth potential, and dominant market position.
    • Its high profitability, efficiency, and sustainable growth rates suggest a strong competitive advantage and a track record of value creation for shareholders.

  8. Key Risks and Considerations:

    • Investors should be aware of potential risks associated with its lower liquidity ratios and higher debt-to-equity ratio.
    • The fluctuating nature of its growth rates suggests that its future performance may be subject to cyclical factors or market conditions.

  9. Overall Assessment:

    • SYK exhibits strong financial health and performance relative to its peer group and industry averages.
    • Its strong profitability, efficiency, and growth prospects are reflected in its premium valuation.
    • While some liquidity and debt metrics are below peer averages, its overall financial position is considered healthy and sustainable.
    • SYK's dominant market position and strong growth trends suggest a promising future outlook.